Allergan plc. (NYSE AGN) has announced that rapastinel (GLYX-13), once-weekly intravenous Phase 3-ready molecule, has achieved the Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) to be used as a secondary treatment...
Your sleepful night is just one step away.
You sleep, we work.
8. Popular Categories